07
Jul
Diamond Biofund > 2025 > Announcement for the changes in the numbers of shares and their fair value held in the Company’s portfolio as well as the Company’s BVPS and cash balance.
2025-07-07

Announcement for the changes in the numbers of shares and their fair value held in the Company’s portfolio as well as the Company’s BVPS and cash balance.

分享

發布日期：2025-07-07

來源：鑽石生技投資股份有限公司

No 1 Date of announcement 2025/07/07 Time of announcement 17:18:20
Subject

Announcement for the changes in the numbers of shares and their fair value held in the Company’s portfolio as well as the Company’s BVPS and cash balance.
Date of events 2025/07/07 To which item it meets paragraph 51
  1. Date of occurrence of the event:2025/06/06
  2. Company name:Diamond Biofund Inc.
  3. Relationship to the Company (please enter ”head office” or”subsidiaries”):Head office.
  4. Reciprocal shareholding ratios:N/A
  5. Cause of occurrence:In accordance with the official letter No.1121802934 issued by Taiwan Stock Exchange Corporation on 2023/06/29. The Company is required to announce for the changes in the numbers of shares held in the Company’s portfolio, changes in their fair value and the Company’s book value per share and cash and cash equivalent balances on a monthly basis.
  6. Countermeasures:
    (1) The Company’s changes in the numbers of the portfolio’s shares held by the Company and changes in their fair value in June 2025 are as follows:

                                 (Units:shares; NT$ thousand)

Portfolio
Company		 Numbers of Shares
held by the company
on 2025/06/30		 Numbers of Shares
held by the company
on 2025/05/31		 Changes in the
numbers of 
Portfolio’s shares
held by the 
company		 Changes in 
fair value
CHO Pharma Inc. 30,869,000 30,869,000 – 8,335
StemCyte
International Ltd.		 22,966,150 22,966,150 226,000 26,957
Theia Medical 
Technology Co. Ltd.		 9,042,648 9,042,648 – (167)
Sinew Pharma Inc. 6,696,209 6,696,209 – (3,482)
EyeYon Medical Ltd. 59,018 59,018 – (1,762)
Tetanti AgriBiotech Inc. 7,900,000 7,900,000 – 5,214
Kendall Capital 
Partners I, L. P		 N/A N/A N/A (1,145)
Bilayer Therapetics,
Inc.		 915,540 915,540 – 18
ImmunAdd Inc. 4,259,999 4,259,999 – (3,195)
Rejuvenate Bio N/A N/A N/A 0
Syncell Inc. 10,367,059 10,367,059 – (4,043)
Diamond Biofund 
I Inc.		 200,000,000 200,000,000 – (11,857)
Diamond Biofund 
II Inc.		 200,000,000 200,000,000 – (13,594)
Total       1,279

(2) The Company’s book value per share and cash and cash equivalent balances are as follows:

Date Book Vale
Per Share (NT$)		 Cash and Cash equivalent
(NT$ thousand)
2025/06/30 11.00 3,030,709

  1. Any other matters that need to be specified (the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):
    The Company’s main investment area is biotechnology, whose stock price and fair value is greatly affected by research and development results, causing relatively large fluctuations. Therefore, if the fair value of the portfolio declines in the current year, the Company’s operating revenue may be negative.
No 1 Date of announcement 2025/07/07 Time of announcement 17:18:20
Subject

Announcement for the changes in the numbers of shares and their fair value held in the Company’s portfolio as well as the Company’s BVPS and cash balance.
Date of events 2025/07/07 To which item it meets paragraph 51
  1. Date of occurrence of the event:2025/06/06
  2. Company name:Diamond Biofund Inc.
  3. Relationship to the Company (please enter ”head office” or”subsidiaries”):Head office.
  4. Reciprocal shareholding ratios:N/A
  5. Cause of occurrence:In accordance with the official letter No.1121802934 issued by Taiwan Stock Exchange Corporation on 2023/06/29. The Company is required to announce for the changes in the numbers of shares held in the Company’s portfolio, changes in their fair value and the Company’s book value per share and cash and cash equivalent balances on a monthly basis.
  6. Countermeasures:
    (1) The Company’s changes in the numbers of the portfolio’s shares held by the Company and changes in their fair value in June 2025 are as follows:

(Units:shares; NT$ thousand)

Portfolio
Company		 Numbers of Shares
held by the company
on 2025/06/30		 Numbers of Shares
held by the company
on 2025/05/31		 Changes in the
numbers of
Portfolio’s shares
held by the
company		 Changes in
fair value
CHO Pharma Inc. 30,869,000 30,869,000 – 8,335
StemCyte
International Ltd.		 22,966,150 22,966,150 226,000 26,957
Theia Medical
Technology Co. Ltd.		 9,042,648 9,042,648 – (167)
Sinew Pharma Inc. 6,696,209 6,696,209 – (3,482)
EyeYon Medical Ltd. 59,018 59,018 – (1,762)
Tetanti AgriBiotech Inc. 7,900,000 7,900,000 – 5,214
Kendall Capital
Partners I, L. P		 N/A N/A N/A (1,145)
Bilayer Therapetics,
Inc.		 915,540 915,540 – 18
ImmunAdd Inc. 4,259,999 4,259,999 – (3,195)
Rejuvenate Bio N/A N/A N/A 0
Syncell Inc. 10,367,059 10,367,059 – (4,043)
Diamond Biofund
I Inc.		 200,000,000 200,000,000 – (11,857)
Diamond Biofund
II Inc.		 200,000,000 200,000,000 – (13,594)
Total 1,279

(2) The Company’s book value per share and cash and cash equivalent balances are as follows:

Date Book Vale
Per Share (NT$)		 Cash and Cash equivalent
(NT$ thousand)
2025/06/30 11.00 3,030,709

  1. Any other matters that need to be specified (the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):
    The Company’s main investment area is biotechnology, whose stock price and fair value is greatly affected by research and development results, causing relatively large fluctuations. Therefore, if the fair value of the portfolio declines in the current year, the Company’s operating revenue may be negative.